201 related articles for article (PubMed ID: 17072088)
21. Establishment of a mouse model of troglitazone-induced liver injury and analysis of its hepatotoxic mechanism.
Jia R; Oda S; Tsuneyama K; Urano Y; Yokoi T
J Appl Toxicol; 2019 Nov; 39(11):1541-1556. PubMed ID: 31294483
[TBL] [Abstract][Full Text] [Related]
22. Hepatotoxicity of the thiazolidinediones.
Tolman KG; Chandramouli J
Clin Liver Dis; 2003 May; 7(2):369-79, vi. PubMed ID: 12879989
[TBL] [Abstract][Full Text] [Related]
23. Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry.
Alvarez-Sanchez R; Montavon F; Hartung T; Pähler A
Chem Res Toxicol; 2006 Aug; 19(8):1106-16. PubMed ID: 16918252
[TBL] [Abstract][Full Text] [Related]
24. In vitro investigation of the glutathione transferase M1 and T1 null genotypes as risk factors for troglitazone-induced liver injury.
Usui T; Hashizume T; Katsumata T; Yokoi T; Komuro S
Drug Metab Dispos; 2011 Jul; 39(7):1303-10. PubMed ID: 21511944
[TBL] [Abstract][Full Text] [Related]
25. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate.
Funk C; Pantze M; Jehle L; Ponelle C; Scheuermann G; Lazendic M; Gasser R
Toxicology; 2001 Oct; 167(1):83-98. PubMed ID: 11557132
[TBL] [Abstract][Full Text] [Related]
26. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.
Funk C; Ponelle C; Scheuermann G; Pantze M
Mol Pharmacol; 2001 Mar; 59(3):627-35. PubMed ID: 11179459
[TBL] [Abstract][Full Text] [Related]
27. Hepatotoxicity with thiazolidinediones: is it a class effect?
Scheen AJ
Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
[TBL] [Abstract][Full Text] [Related]
28. Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties.
Saha S; Chan DS; Lee CY; Wong W; New LS; Chui WK; Yap CW; Chan EC; Ho HK
Eur J Pharmacol; 2012 Dec; 697(1-3):13-23. PubMed ID: 23041271
[TBL] [Abstract][Full Text] [Related]
29. Effect of thiazolidinediones on bile acid transport in rat liver.
Snow KL; Moseley RH
Life Sci; 2007 Jan; 80(8):732-40. PubMed ID: 17126857
[TBL] [Abstract][Full Text] [Related]
30. Increased susceptibility to troglitazone-induced mitochondrial permeability transition in type 2 diabetes mellitus model rat.
Segawa M; Sekine S; Sato T; Ito K
J Toxicol Sci; 2018; 43(5):339-351. PubMed ID: 29743445
[TBL] [Abstract][Full Text] [Related]
31. Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect.
Enokizono J; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Feb; 35(2):209-14. PubMed ID: 17093005
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells.
Yamamoto Y; Nakajima M; Yamazaki H; Yokoi T
Life Sci; 2001 Dec; 70(4):471-82. PubMed ID: 11798015
[TBL] [Abstract][Full Text] [Related]
33. Bile Salt Homeostasis in Normal and Bsep Gene Knockout Rats with Single and Repeated Doses of Troglitazone.
Cheng Y; Chen S; Freeden C; Chen W; Zhang Y; Abraham P; Nelson DM; Humphreys WG; Gan J; Lai Y
J Pharmacol Exp Ther; 2017 Sep; 362(3):385-394. PubMed ID: 28645914
[TBL] [Abstract][Full Text] [Related]
34. Involvement of different human glutathione transferase isoforms in the glutathione conjugation of reactive metabolites of troglitazone.
Okada R; Maeda K; Nishiyama T; Aoyama S; Tozuka Z; Hiratsuka A; Ikeda T; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2011 Dec; 39(12):2290-7. PubMed ID: 21914835
[TBL] [Abstract][Full Text] [Related]
35. Biological reactive intermediates in drug discovery and development: a perspective from the pharmaceutical industry.
Baillie TA; Kassahun K
Adv Exp Med Biol; 2001; 500():45-51. PubMed ID: 11764978
[No Abstract] [Full Text] [Related]
36. Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?
Mazerbourg S; Kuntz S; Grillier-Vuissoz I; Berthe A; Geoffroy M; Flament S; Bordessa A; Boisbrun M
Curr Top Med Chem; 2016; 16(19):2115-24. PubMed ID: 26881718
[TBL] [Abstract][Full Text] [Related]
37. Activation of a retinoic acid receptor pathway by thiazolidinediones induces production of vascular endothelial growth factor/vascular permeability factor in OP9 adipocytes.
Kotake D; Hirasawa N
Eur J Pharmacol; 2013 May; 707(1-3):95-103. PubMed ID: 23542713
[TBL] [Abstract][Full Text] [Related]
38. Troglitazone improves blood flow by inhibiting neointimal formation after balloon injury in Otsuka Long-Evans Tokushima fatty rats.
Min KM; Park SW; Cho KY; Song MS; Kim DK; Park GS; Lee MK
Metabolism; 2002 Aug; 51(8):998-1002. PubMed ID: 12145772
[TBL] [Abstract][Full Text] [Related]
39. Incorporation of an oxygen from water into troglitazone quinone by cytochrome P450 and myeloperoxidase.
He K; Talaat RE; Woolf TF
Drug Metab Dispos; 2004 Apr; 32(4):442-6. PubMed ID: 15039298
[TBL] [Abstract][Full Text] [Related]
40. New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.
Colin C; Salamone S; Grillier-Vuissoz I; Boisbrun M; Kuntz S; Lecomte J; Chapleur Y; Flament S
Breast Cancer Res Treat; 2010 Nov; 124(1):101-10. PubMed ID: 20054646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
